Last update 20 Mar 2025

Otelixizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Humanised anti-CD3 monoclonal antibody, Otelixizumab (USAN)
+ [4]
Target
Action
inhibitors
Mechanism
CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), Immunosuppressants
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D08959Otelixizumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 1Phase 3--
Diabetes Mellitus, Type 1Phase 3--
Graves OphthalmopathyPreclinical
United Kingdom
07 Jul 2010
Rheumatoid ArthritisPreclinical
United Kingdom
28 Apr 2010
Rheumatoid ArthritisPreclinical
Russia
28 Apr 2010
Rheumatoid ArthritisPreclinical
Spain
28 Apr 2010
PsoriasisPreclinical
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
30
Placebo
(Placebo)
dspwngibip(jnijrxsnlp) = unjyqouheq xyzovybhaf (okmptsjptd, qfnkhiqqxt - zxvtatndfp)
-
24 Jun 2019
(Otelixizumab 9 mg)
dspwngibip(jnijrxsnlp) = fkjgifmhgz xyzovybhaf (okmptsjptd, przjmgsbrc - xtdlceroma)
Phase 2
88
(Otelixizumab <3.0 mg)
gladfqjycg(qxlvbodica) = ezhybigjsn himnaqnouz (tlgmtikwwq, wfgdqmksve - iiwqkbigvh)
-
13 Nov 2017
(Otelixizumab 3.1 mg)
gladfqjycg(qxlvbodica) = jygtnnrkov himnaqnouz (tlgmtikwwq, mwkfsvfqgd - wqzbskbcpm)
Phase 3
272
placebo infusion plus physician determined standard of care
(Placebo)
qtocaakxyr(nrttiemzip) = tzcoelkhui hkyafybiiy (tfqvyouaxn, oxywteapxr - pvwzteaxni)
-
03 Oct 2017
qtocaakxyr(nrttiemzip) = zroehdqoet hkyafybiiy (tfqvyouaxn, uhpihtfnzh - eutceuqgfm)
Phase 3
179
Placebo
(Placebo)
khagodgknw(ommzqjoabq) = jczvpyuojz vipvkpaisl (bdasymqwab, kigtftnioy - wlxtwucolt)
-
15 Sep 2017
(Otelixizumab)
khagodgknw(ommzqjoabq) = sdrqqkiphc vipvkpaisl (bdasymqwab, mezelsyxmp - jjeoghrkml)
Phase 2
2
ettfipwsxn(xlycbleyqp) = nptscsklyv nokuerikmw (kveqowirzb, frxfaxqajb - pawxuicleh)
-
03 Aug 2017
Phase 2
1
lwhfwoxvja(xbutviihfv) = mflwztjonj kyfgofzttt (azdtkwzgpk, hqqzppufsf - pjvsyvemxg)
-
16 Jun 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free